Skip to main content

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

TCRR holding history

TCR2 Therapeutics Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TCRR overviewAll 13F holders of TCRRFull Q2 2026 holdings

Shares (Q2 2023)
0
Sold out in Q2 2023
Value
$0
% of portfolio
0.0%
Quarters held
9
Since Q1 2021
Holdings of TCRR by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20230$00.0%−155,390−100.0%Sold outHolders
Q1 2023155,390$233.1K<0.1%+108,995+234.9%AddedHolders
Q4 202246,395$46.3K<0.1%−26,853−36.7%ReducedHolders
Q3 202273,248$131.0K<0.1%−76,335−51.0%ReducedHolders
Q2 2022149,583$434.0K<0.1%−137,819−48.0%ReducedHolders
Q1 2022287,402$794.0K<0.1%−160,928−35.9%ReducedHolders
Q4 2021448,330$2.09M<0.1%+318,953+246.5%AddedHolders
Q3 2021129,377$1.10M<0.1%−27,203−17.4%ReducedHolders
Q2 2021156,580$2.57M<0.1%+155,079+10,331.7%AddedHolders
Q1 20211,501$33.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.